Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 2/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 4/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 4/20 | 0.53 |
| ▸ | CASP1 | P29466 | 3/20 | 0.53 |
| ▸ | CASP7 | P55210 | 3/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29500570 | 1.00 | BACE1 (0.56) | BACE1BACE2MMECTSDFNTA | |
| SCHEMBL29415207 | 0.93 | BACE1 (0.62) | BACE1BACE2CTSDOPRD1 | |
| SCHEMBL29530803 | 0.92 | BACE1 (0.56) | BACE1BACE2CTSDFNTAFNTB | |
| SCHEMBL30974146 | 0.92 | MME (0.54) | BACE1BACE2MMECTSDOPRD1 | |
| SCHEMBL29350741 | 0.91 | FNTA (0.56) | BACE1BACE2MMECTSDFNTA | |
| SCHEMBL31206305 | 0.90 | BACE1 (0.62) | BACE1BACE2CTSDFNTAFNTB | |
| SCHEMBL17305518 | 0.90 | BACE1 (0.62) | BACE1BACE2CTSDFNTAFNTB | |
| SCHEMBL31199120 | 0.90 | BACE1 (0.54) | BACE1BACE2MMECTSDOPRD1 | |
| SCHEMBL2878352 | 0.90 | MME (0.66) | MME | |
| SCHEMBL29498365 | 0.90 | MME (0.66) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112912383-B | Peptide compounds | 优拓制药公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11981755-B2 | Peptide compounds | ULTUPHARMA AB (SE) | 2024-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981755-B2 | Peptide compounds | VIP, NGLY1, TLR5 | BACE1 2998/4885BACE2 2728/4885MME 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.